Chinese Ministry of Health issues guidance to strengthen anti-bribery control at public hospitals *

China - September 6 2012
On August 1, 2012, the Ministry of Health of China (“MOH”) issued the draft Guidance on Strengthening Anti-Bribery Control at Public Hospitals.

Co-authors: Scott Bass, James C. Stansel, Chen Yang, Zhengyu Tang.

---

SFDA to enforce blacklist system for unsafe drug and device products *

China - August 21 2012
Beginning October 1, 2012, China’s State Food and Drug Administration (SFDA), including its provincial counterparts, will implement a nationwide information disclosure system called the Drug Safety Blacklist (“Blacklist”), which includes medical device products as well.

Co-authors: Scott Bass, James C. Stansel, Chen Yang, Zhengyu Tang.

---

SFDA intends to further regulate packaging and labeling of medical devices imported to China *

China - May 24 2012
On May 21, 2012, China’s State Food and Drug Administration (SFDA) issued a draft Notice on Further Regulating Labeling and Packaging of Medical Devices Manufactured Overseas.

Co-authors: Chen Yang, Zhengyu Tang.

---

Updates on international pricing issues for pharmaceutical and biologic products *

China, European Union, France, Germany, United Kingdom, USA - May 18 2012
Sidley Austin LLP’s Global Life Sciences Team is pleased to provide you with this Global Pricing Newsletter, the first in a periodic series updating clients and friends of the firm on pricing issues around the world that may have an impact on pharmaceutical and biologic manufacturers’ legal and business strategies.

Co-authors: William Sarraille, Maarten Meulenbelt, James C. Stansel, Trevor L. Wear, Felix von Bredow.

---

NDRC takes serial measures to reduce drug prices *

China - May 14 2012
It has long been a policy objective of the Chinese Government to reduce drug prices in China while ensuring drug quality.

Co-authors: Chen Yang, Zhengyu Tang.

---